Key result
Angiotensin II type 1 receptor (AT1R) antibodies are associated with allograft rejection and decreased graft survival in kidney transplantation.
Why the study?
Assessing AT1R antibodies along with donor-specific HLA antibodies may identify patients at risk for allograft injury and improve kidney transplantation outcomes.
Does monitoring AT1R antibodies predict allograft rejection and graft survival in kidney transplant recipients?
Does monitoring AT1R antibodies predict allograft rejection and graft survival in kidney transplant recipients?
Answers are grounded in this paper and cite their sources.
Monitoring AT1R antibodies in kidney transplant recipients may help identify patients at risk for antibody-mediated rejection and graft failure, especially in the absence of donor-specific HLA antibodies.
Angiotensin II type 1 receptor (AT1R) antibodies directly injure endothelial and vascular smooth muscle cells by activating transcription factors associated with proinflammatory responses. Previous studies have shown that AT1R antibodies are associated with allograft rejection and decreased graft survival in kidney transplantation. Development of enzyme-linked immunosorbent assay has facilitated semiquantitative detection of AT1R antibodies. Assessing AT1R antibodies along with donor specific human leukocyte antigen antibodies may have potential to identify patients with possible risk for allograft injury and improve overall outcomes. In this review, we summarize recent clinical studies about AT1R antibodies in kidney transplantation and provide perspectives for future research area.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2019) conducted a review in Kidney transplantation. Angiotensin II type 1 receptor (AT1R) antibodies was evaluated. Angiotensin II type 1 receptor (AT1R) antibodies are associated with allograft rejection and decreased graft survival in kidney transplantation.
Synapse has enriched 10 related papers. Consider them for comparative context: